Cisplatin

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Cisplatin is a highly effective and broad-spectrum chemotherapeutic agent [1].
    Cisplatin is an anticancer agent with some side effects. It is believed to induce apoptosis through several mechanisms. The traditional mechanism is that cisplatin enters the cell, interacts with the DNA guanine bases and forms the inter- or intra-strand chain cross-linking, then prevents the replication of DNA. This formation can also induce apoptosis by activating p53. Cisplatin was also found to cause ROS generation and increase lipid peroxidation, which leads cells to the apoptotic pathway. In addition, cisplatin induces apoptosis with the caspase-dependent pathway. In cochlear cells, cisplatin treatment results in the increase of caspases-3 and -9 and causes the cochlear damage side effect [1].
    
    [1] Casares C, Ramírez-Camacho R, Trinidad A, et al. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. European Archives of Oto-Rhino-Laryngology, 2012, 269(12): 2455-2459.
- Properties
  - Alternative Name
    
    CDDP; azane;dichloroplatinum(2+)
    
    CAS Number
    
    15663-27-1
    
    Molecular Formula
    
    Cl2H6N2Pt
    
    Molecular Weight
    
    300.05
    
    Appearance
    
    A solid
    
    Purity
    
    99.84%
    
    Solubility
    
    insoluble in EtOH; insoluble in H2O; ≥12.5 mg/mL in DMF
    
    Storage
    
    Store at RTIt is recommended to store in the form of powder in the dark, the solution is very unstable (Prepare Solution fresh and use at room temperature), DMF is recommended, DMSO can inactivate Cisplatin's activity.
    
    * For Research Use Only
- Reference
  - 1. JING CHU, JINGHAI GAO, et al. "Mechanism of hydrogen on cervical cancer suppression revealed by high‑throughput RNA sequencing." Oncol Rep. 2021 Jul;46(1):141. PMID:34080660
    2. Gang Wang, Qikai Sun, et al. "The stabilization of yes-associated protein by TGFβ-activated kinase 1 regulates the self-renewal and oncogenesis of gastric cancer stem cells." J Cell Mol Med. 2021 Jul;25(14):6584-6601. PMID:34075691
    3. Cheng-Wei Chou, Ri-Yao Yang, et al. "The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer." Am J Cancer Res 2020 Aug 1;10(8):2621-2634. PMID:32905506
    4. Guo J, Xu G, et al. "Low Expression of Smurf1 Enhances the Chemosensitivity of Human Colorectal Cancer to Gemcitabine and Cisplatin in Patient-Derived Xenograft Models." Transl Oncol. 2020;13(9):100804. PMID:32512228
    5. Li A, Cao W, et al. "Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells." J Cancer Res Clin Oncol. 2020;146(7):1737-1749. PMID:32342201
    6. Mikhail Chesnokov, Imran Khan, et al. "The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma." bioRxiv. 2019 September 16.
    7. Chen Z, Tian D, et al. "Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells." Front Pharmacol. 2019 Mar 22;10:260. PMID:30967777
    8. Zhang B, Cui B, et al. "ATR activated by EB virus facilitates chemotherapy resistance to cisplatin or 5-fluorouracil in human nasopharyngeal carcinoma." Cancer Manag Res. 2019 Jan
    9;11:573-585. PMID:30666155
    9. Wu Q, Wei X, et al. "Bionic 3D spheroids biosensor chips for high-throughput and dynamic drug screening." Biomed Microdevices. 2018 Sep 15;20(4):82. PMID:30220069
    10. Yeo SK, Paul R, et al. "Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer." Autophagy. 2018;14(7):1214-1225. PMID:29938573
    11. Sharma K, Vu TT, et al. "p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells." Mol Oncol. 2018 Jan 19. PMID:29352505
    12. Lochmann TL, Floros KV, et al. "Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression." Clin Cancer Res. 2018 Jan 15;24(2):360-369. PMID:29118061

Cisplatin

Background

We Also Recommend

LDN-193189

Neratinib (HKI-272)

WP1130